Calcium Channel Autoantibodies Predicted Sudden Cardiac Death and All-Cause Mortality in Patients with Ischemic and Nonischemic Chronic Heart Failure

Table 4

The association between CC-AAbs and the prognosis of CHF patients.

	Control (𝑛=834)		DCM (𝑛=732)			ICM (𝑛=1099)
	CC-AAb(+)	HR	CC-AAb(+)	HR (95% CI)	𝑃	CC-AAb(+)	HR (95% CI)	𝑃
Total 𝑛 (%)	10 (1.20%)	1	43 (5.87%)	1	<0.001	51 (4.64%)	1	<0.001
No death 𝑛 (%)	10 (1.20%)	1	20 (4.13%)	1	0.030	22 (3.17%)	1	0.178
All-cause death, 𝑛 (%)	0	1	23 (9.27%)	1.733 (1.042–2.883)	0.034	29 (7.88%)	2.219 (1.461–3.371)	<0.001
Non-SCD 𝑛 (%)	0	1	10 (6.85%)	1.049 (0.483–2.278)	0.903	17 (5.74%)	1.887 (1.081–3.293)	0.025
SCD 𝑛 (%)	0	1	13 (12.75%)	3.191 (1.598–6.369)	0.001	12 (11.57%)	2.805 (1.488–5.288)	0.001

The positive of calcium channel autoantibodies (CC-AAbs) increased hazard ratio. 95% confidence interval (95% CI) after adjustment for age, gender, BMI, MHR, hypertension, hyperlipidemia, diabetes mellitus, QTc, PVC, AF, NYHA class, LVEF, causes of HF, and medications. 𝑃<0.05 was considered significant.